T cell activation involves not only recognition of antigen presented by the MHC, but also nonspecific interactions termed "costimulation." The costimulatory molecules B7-1 and B7-2 are ligands on antigen-presenting cells for the CD28 and CTLA-4 receptors on T cells. Previously, a fusion protein consisting of human CTLA-4 linked to human Fc was shown to bind B7-1 and B7-2 with high avidity and to prevent specific T cell activation. Here we investigated the effects of a recombinant fusion protein consisting of the extracellular domain of human CTLA-4 bound to mouse IgG2a Fc (CTLA4-Fc) upon experimental autoimmune encephalomyelitis, a T cell-mediated disease that serves as a model for multiple sclerosis. CTLA4-Fc prevented experimental autoimmune encephalomyelitis in 26 of 28 CTLA4-Fc-treated mice (median maximum score 0), whereas 28 of 30 mice treated with control mouse IgG2a developed disease (median maximum score 2.75). Less inflammation and virtually no demyelination or axonal loss occurred in CTLA-4-Fc-treated compared with control-treated mice. Activated splenocytes from CTLA4-Fc-treated mice were able to transfer disease adoptively to naive recipients. These results indicate a key role for the B7/CD28 system in the development of actively induced murine experimental autoimmune encephalomyelitis, suggesting an area of investigation with therapeutic potential for multiple sclerosis. (J. Clin. Invest. 1995.95:2783-2789
Introduction
Antigen-specific T cell activation requires not only the TCRmediated signal after recognition by the TCR of processed antigen presented in the context of MHC molecule, but also a second, nonspecific signal, termed costimulation, that is the result of other receptor-ligand interactions ( 1) . One costimulatory pathway involves the interaction of B7-1 and B7-2 mole-cules on antigen-presenting cells with the CD28 molecule on T cells and results in paracrine levels of IL-2 secretion and proliferation (2) (3) (4) (5) (6) . Importantly, inhibition of CD28 costimulation in conjunction with delivery of the TCR-mediated signal can result in T cell anergy or hyporesponsiveness (7) (8) (9) . CTLA-4 is a second receptor on T cells for B7-1 and B7-2 (10) and is homologous to CD28 (11) . Although CTLA-4 binds B7-1 with 20-fold higher avidity than CD28 (10), a clear role for CTLA-4 in T cell activation has not been demonstrated (12) . Because CTLA-4 binds to B7-1 and B7-2 with high avidity and this binding occurs across species (13) , a fusion protein of human CTLA-4 and the Fc region of Ig has been useful in studies of the effects of inhibition of CD28 costimulation. CTLA-4-Fc has been shown to inhibit specific T cell activation both in vitro (10) and in vivo (14) (15) (16) (17) .
To investigate a role for CD28 costimulation in central nervous system (CNS) autoimmune demyelination, we used experimental autoimmune encephalomyelitis (EAE),' a T cell-mediated inflammatory demyelinating disease that serves as a prime model for human multiple sclerosis (MS) ( 18, 19) . EAE is known to be induced by CD4+ T cells (20, 21) . The pathogenesis of MS, though not fully understood, also appears to involve activated T cells (22) (23) (24) (25) . The current studies investigated in EAE the effects of systemic therapy with a recombinant fusion protein consisting of human CTLA-4 and murine IgG2a Fc upon the clinical course, CNS histologic changes, and generation of encephalitogenic, IL-2-producing T cells.
Methods
Mice. Pathogen-free female SJL/J mice aged 6-12 wk (the Jackson Laboratories, Bar Harbor, ME) were housed and maintained in microisolator cages in accordance with guidelines of the Washington University Committee for the Humane Care of Laboratory Animals and the National Institutes of Health regarding laboratory animal welfare. Sentinel mice were periodically checked for infection, and none was found.
Antigens and EAE induction. CNS myelin was purified from guinea pig spinal cords (Rockland, Gilbertsville, PA) as described (26) , emulsified in a 1:1 mixture of sterile saline and complete Freund's adjuvant (Difco Laboratories Inc., Detroit, MI), and injected subcutaneously at two sites on the back (base of tail and dorsal neck) to induce EAE. Each mouse received 0.5 mg of whole myelin in 0.1 ml of emulsion and 200 ng of pertussis toxin (List Laboratories, Campbell, CA) dissolved in 100 Ml of sterile PBS administered intravenously on days 0, 2, and 7 postimmunization (PI). Clinical disease was scored from 0 to 5 in a blind fashion at least 6 d/wk according to accepted criteria (20). Re-lapses were defined as worsening by at least 1 point lasting at least 2 d. Mice were weighed weekly during the acute EAE time period.
CTLA-4-Fc and control 1g. A soluble fusion protein consisting of the extracellular domain of human CTLA-4 and a mouse IgG2a Fc was prepared. The Fc region of mouse IgG2a was generated by reverse transcription followed by PCR amplification using poly(A)' RNA isolated from the L243 hybridoma cell line (ATCC HB 55; American Type Culture Collection, Rockville, MD) and the IgG2a-specific sense primer 5'-GATCGGATCCGAGCCCAGAGGGCCCACAATCAAGCC-3' and antisense primer 5'-GATCAAGCTTAGATCTTATCATTTACC-CGGAGTCCGGGAGAA-3' (27) . The purified PCR product was digested with BamHI and BglII and cloned into the BamHI site of pMON3360B (28), yielding plasmid pMON24210. The signal peptide and extracellular domain of CTLA-4 was generated by PCR amplification using a thymus cDNA library (HL1074a; Clontech, Palo Alto, CA) as template and the CTLA-4-specific sense primer 5 '-CCATGGATC-CATGGCTTGCCTTGGATTTCAG-3' and the antisense primer 5'-GATCGGATCCGAAGTCAGAATCTGGGCACGGTTC-3' (11). The purified BamHI digested product was cloned into the BamHI site of pMON24210, yielding transfection vector pMON24218. Transfection and isolation of a stable cell line expressing 2-5 pig/ml CTLA-4-Fc were performed as previously described (28) blindly from 0 to 5' for inflammation, demyelination, axonal necrosis (30) . These data were subjected to statistical analysis.
Proliferation assays. Guinea pig myelin basic protein (MBP) was purified from guinea pig spinal cords (Rockland, Gilbertsville, PA) as described (31) . Proteolipid protein (PLP) was purified from normal brain obtained at autopsy as described (32) . The (X) . Treatments began at day 1 and ceased on day 18 . Mice sacrificed for histology are denoted by an asterisk. The grade 4.5 control-treated mouse (A) perfused on day 16 was sacrificed owing to its moribund state. By study design, a CTLA-4-Fc-treated counterpart was perfused at the same time.
mice from the two treatment groups according to published methods (34) . Briefly, the supernatants of 48-h cultures activated with 20 ug/ ml PLP139-151 were added in serial dilutions in triplicate to CTLL-2 cells seeded in 96-well, flat-bottomed plates, and proliferation of the CTLL-2 cells was measured by incorporation of tritiated thymidine as previously described. In preliminary experiments, the ability of SCs to generate IL-2 was shown to be dependent on peptide 139-151 dose, with 20 ,g/ml as an optimal dose. To assess the contribution of IL-2 versus 1L-4 to CTLL-2 proliferation, 50 ,g/ml rat anti-IL-2 mAb (31 /Lg/ml neutralized 1 U/ml IL-2; Genzyme Corp., Boston, MA) was added to wells containing 12.5-100% supernatant in parallel to untreated wells. 21 PI (both pairs from experiment 1). Blinded scoring of all levels of the CNS for inflammation, demyelination, and axonal necrosis revealed significantly less inflammation (P = 0.004), demyelination (P = 0.004), and necrosis (P = 0.022) in the CTLA4-Fc-treated group overall. Demyelination and axonal necrosis were almost absent in the CNS of CTLA-4-Fc-treated mice when compared with the CNS of control-treated mice (Fig. 2, a and b) . (Fig. 3) Inflammation, demyelination, and axonal necrosis were scored as described in Methods. Numbers represent the mean score of two to four slides. ,ug/ml PLP 139-151 in six separate experiments. CTLL-2 proliferation was abolished by the addition of antibody to IL-2, confirming that IL-2 (and not IL-4) was responsible for CTLL-2 cell proliferation. Decreased IL-2 was noted in the supernatants of SCs derived from the CTLA-4-Fc-treated mice when compared with the control-treated mice (Fig. 4) .
Serial transfer experiments. To determine whether T cells capable of inducing EAE were present and functional in CTLA-4-Fc-treated mice, SCs from CTLA-4-Fc-treated mice were activated by culturing with antigen or mitogen for 48 h before transfer into normal SJL females. PLP peptide-activated SCs from CTLA-4-Fc-treated mice activated with the encephalitogenic 139-151 amino acid peptide of PLP transferred typical clinical EAE into four of four naive recipients, with all animals unequivocally ill by day 9 after cell transfer. The maximum clinical scores of these animals were 2.0, 2.5, 2.5, and 3.5. SCs from control-treated mice also transferred EAE into two of two recipients after activation in vitro with PLP 139-151, with maximum clinical scores of 2.0 and 4.0 and onset by day 9 after transfer. SCs from neither CTLA4-Fc-nor control-treated mice transferred EAE after a 2-d culture with MBP or Con A, even though large numbers of cells (108) were transferred. Histologic analysis was performed on the CNS of two of the six recipients of PLP peptide-activated SCs from CTLA4-Fctreated mice, revealing marked inflammation and demyelination and mild to moderate axonal necrosis in both cases, which are typical histologic features of EAE (29) . Discussion EAE serves as a prime model for the study of T cell-mediated inflammatory CNS demyelination, as observed in MS. A variety of therapies directed at disease-inducing T cells (e.g., 35-39) have been effective in inhibiting EAE induced in highly inbred rodent strains with a known antigen, though none have yet been successfully applied in the treatment of ("outbred") MS patients. As with other T cell-mediated autoimmune diseases, the ideal therapy for MS should inhibit putative autoimmune T cells without interfering with the normal immune functions of other T cells. Practically, MS therapies must be effective despite being first administered after initiation of the immune event and should not depend upon precise knowledge of the autoantigen. In the present work, a controlled, blinded study of the effect of the fusion protein CTLA-4-Fc upon murine EAE induced with CNS myelin was performed. We found a profound inhibition of the clinical and histologic manifestations of EAE, which continued after cessation of treatment with CTLA-4-Fc. These findings implied that costimulation delivered through CD28 was necessary for the function of EAE-inducing cells in this model for MS, since CTLA-4-Fc acts by blocking the CD28 ligands, B7-1 and B7-2. Myelin antigen-specific T cell proliferation was decreased but present in CTLA4-Fc-treated mice. Blockade of costimulation, by preventing the activation of T cells, would be expected to prevent the production of large quantities of IL-2 and result in the decreased production of other lymphokines (40), which have been implicated in the pathogenesis of EAE and MS (41) (42) (43) (44) (45) (46) . Previously, a recombinant fusion protein of human CTLA-4 and human Fc was found to block the B7-1 /B7-2:CD28 signaling pathway. This CTLA-4-Ig has been shown to inhibit T cell proliferation and IL-2 jploduction in primary in vitro responses and to induce T cell hyporesponsiveness or anergy to subsequent antigen challenge (6, 8, 9) . CTLA-4-Fc was shown to induce a state of long-term donor-specific tolerance in a xenogeneic pancreatic islet cell transplant model ( 14) , compatible with T cell anergy. In other studies involving cardiac allograft transplantation using the same fusion protein, long-lasting tolerance was not achieved, although graft survival was modestly prolonged (16) . In a related study, it was found that CTLA-4-Fc, when administered with donor-specific transfusion, was effective even after introduction of specific antigen, suggesting that it was acting upon events involved in the amplification rather than induction of the specific T cell immune response (17) . In further support of this notion, a recent study showed effective treatment of established murine lupus-like disease using CTLA-4-Ig (47 (51) (52) (53) (54) can occur. Thus, the possibility exists that intervention to block CD28 costimulation, even after the initiation of a CNS autoimmune process and the generation of memory T cells to one antigen, might prevent progression by blocking antigenic determinant spreading. The present data, indicating a crucial role for CD28 costimulation in actively induced EAE, suggest an area of investigation with potential for inhibition of the putative T cellmediated autoimmune response in MS, even despite our current lack of knowledge of the identity of the MS autoantigen(s).
